share_log

Sanofi | 6-K: Sanofi Announces Agreement for Potential First-in-Class Vaccine Against Extraintestinal Pathogenic E. Coli and Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment

赛诺菲安万特 | 6-K:赛诺菲安万特宣布就潜在的第一类抗肠道外致病性大肠杆菌疫苗达成协议及赛诺菲安万特和梯瓦宣布独家合作提供炎症性肠病治疗药物

SEC announcement ·  2023/10/11 06:05
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息